Novo Nordisk A/S (NYSE:NVO) Stock Position Boosted by Pinnacle Bancorp Inc.

Pinnacle Bancorp Inc. grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 29.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,496 shares of the company’s stock after purchasing an additional 336 shares during the quarter. Pinnacle Bancorp Inc.’s holdings in Novo Nordisk A/S were worth $129,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. International Assets Investment Management LLC boosted its position in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the period. DSM Capital Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at $98,765,000. Marshall Wace LLP raised its position in Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after buying an additional 689,441 shares during the period. Finally, Wellington Management Group LLP purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth about $42,017,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $83.26 on Friday. The company has a market capitalization of $373.61 billion, a PE ratio of 26.94, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a one year low of $80.05 and a one year high of $148.15. The company’s fifty day moving average price is $98.82 and its 200 day moving average price is $117.93.

Analyst Ratings Changes

A number of brokerages have recently weighed in on NVO. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.